Transgenomic, Inc. has entered into a collaboration with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations are identified with CE-IVD CRC RAScan kits using Surveyor-Wave technology, and provide physicians with important information regarding tumor mutation status. Financial terms were not disclosed.   “This collaboration with Amgen is indicative of how Transgenomic’s proprietary molecular technologies...